Meridian BioTools • Q2 2024 Program Maturity Review
| Risk | Impact | Status |
|---|---|---|
| Warehouse migration reliability | High | Mitigating |
| Governance framework adoption lag | Med | Active |
| Cost overrun from infra scaling | Med | Monitoring |
| Self-serve plateau below 60% target | Med | Active |
| Legacy tool sunset resistance | Low | Monitoring |
| Business glossary completeness | Med | Active |
| Analyst skill gap in new tools | Med | Training |
| Executive dashboard refresh latency | Low | Resolved Q3 |
Health Index: 83 — Up 4 points QoQ, driven by self-serve adoption gains (+8% to 57%) and reliability recovery post-migration (74→86 sub-index). Governance sub-index remains at P58 benchmark, requiring focused lineage and certification campaigns in Q3.
Program ROI: 3.4× — Exceeded plan by 0.3×. Latency reduction (-1.8 days vs. baseline) delivered $1.6M annualized decision-cycle savings. Fully loaded program cost $1.42M vs. $4.8M value delivered (license avoidance, FTE productivity, faster close cycles).
Forecast Variance: +4% ($120K miss) — Q2 warehouse migration caused 2-week reliability dip, delaying planned automation savings. Recovery complete; Q3 forecast reinstated. Cost Efficiency Index stable at $18 per 1K runs.
Benchmark Position: P72 overall, P58 governance — Industry-leading adoption and ROI; governance maturity lags peers. Recommended action: prioritize certified dataset catalog and lineage tooling investment in H2 budget cycle.